文献速递肺外科

有创分期不能防止I期肺癌淋巴结转移被漏诊

Invasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-04-10

基于STS数据库2012-2017年30685例临床I期肺癌接受肺叶切除的患者,评估有创淋巴结分期对影像学隐匿淋巴结转移漏诊的预防程度。结果显示总体漏诊率14.7%,接受支气管内超声或纵隔镜者漏诊率仍达20.1%和18.2%,提示即使有创分期阴性仍存在明显漏诊风险,需彻底手术淋巴结评估。

要点

  • 临床I期肺癌有创分期后淋巴结转移漏诊率仍高
  • 支气管内超声或纵隔镜后漏诊率分别达20.1%和18.2%
  • 肺门淋巴结最常被漏诊,占9.5%

核心结论

  • 临床I期肺癌患者即使有创淋巴结分期、PET和CT均阴性,隐匿淋巴结转移风险仍显著存在。
  • 缺乏彻底手术淋巴结评估时,早期肺癌患者有治疗不足的风险。

研究设计与样本

  • 回顾性队列研究,使用STS普胸外科数据库2012-2017年临床I期肺癌接受肺叶切除的治疗初治患者,均行PET和CT。
  • 共识别30685例临床I期患者,3895例(12.7%)术前行支气管内超声,3341例(10.9%)行纵隔镜。

主要发现

  • 总体漏诊淋巴结转移(MNM)率为14.7%。
  • 行支气管内超声者MNM率为20.1%(95%CI 18.8%-21.5%),行纵隔镜者为18.2%(95%CI 16.7%-19.6%)。
  • 肺门淋巴结最常被漏诊,占9.5%。
  • 有创分期在肿瘤>2 cm(66.4% vs 50.2%,P<.001)和鳞状细胞组织学(26.9% vs 16.9%,P<.001)中更常见。
  • 按肿瘤大小、组织学、侧别和年龄切点,患者可分为高危(MNM 25%)和低危(MNM 6%)队列。

临床怎么用

  • 临床I期肺癌不应仅依赖术前有创分期阴性结果,应进行彻底的手术淋巴结评估以避免治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Up to 20% of clinical stage I lung cancer patients harbor lymph node metastases that go undetected (missed) during the clinical staging evaluation. We investigated to what degree the addition of invasive nodal staging procedures to imaging, as currently practiced, prevents radiographically occult nodal metastases from being missed during the clinical staging evaluation. METHODS: Treatment-naive patients, imaged by positron emission tomography and computed tomography, who underwent lobectomy for clinical stage I lung cancer from 2012 to 2017 in The Society of Thoracic Surgeons General Thoracic Surgery Database were studied. Rates of missed nodal metastases (MNM) (ie, nodal metastases in lobectomy specimens undetected during clinical staging evaluation) were determined. Risk factors were assessed with multivariable modeling. RESULTS: Of the 30,685 clinical stage I patients identified, 3895 (12.7%) underwent preoperative endobronchial ultrasound and 3341 (10.9%) underwent mediastinoscopy. Invasive staging was more common with tumors > 2 cm (66.4% vs 50.2%, P < .001) and squamous histology (26.9% vs 16.9%, P < .001). MNM were discovered in 14.7% of patients, including 20.1% of patients (95% confidence interval, 18.8%-21.5%) who had undergone endobronchial ultrasound and 18.2% (95% confidence interval, 16.7%-19.6%) who had undergone mediastinoscopy. Hilar nodes were most often "missed" (9.5%). Using cut-points in tumor size, histology, laterality, and age, patients could be stratified into particularly high-risk (25% MNM) and low-risk (6% MNM) cohorts. CONCLUSIONS: Substantial risk of occult lymph node metastases persists in patients with clinical stage I lung cancer despite negative invasive nodal staging, positron emission tomography, and computed tomography. In the absence of a thorough surgical nodal evaluation, early-stage lung cancer patients are at risk of under-treatment.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Resio BJ, Canavan M, Mase V, et al. Invasive Staging Procedures Do Not Prevent Nodal Metastases From Being Missed in Stage I Lung Cancer. Ann Thorac Surg. 2020. PMID: 32283084. doi:10.1016/j.athoracsur.2020.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。